2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27274 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Haris Ali und 1 weiteren Autor:innen. Beteiligte Einrichtung: Divison of Leukemia, Department of Hematology and Hemopoietic Cell Transplantation, City of Hope, Duarte, California, USA. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Background
Allogeneic hemopoietic stem cell transplantation (HSCT) currently remains the only curative treatment for patients with myelofibrosis (MF). Transplant related mortality (TRM) and relapse, remain two significant complications which need to be addressed.
Aims
The aim of this manuscript is to review current available reports on changes which have recently occurred, to improve the outcome of MF patients undergoing an allogeneic HSCT.
Methods
Published papers were used to analyze different aspects of allogeneic HSCT.
Results
Changes and updates are provided on selection of patients, prognostic systems, managing splenomegaly, conditioning regimens, predicting transplant outcome, stem cell sources, stem cell donors, graft versus host disease (GvHD) prophylaxis, patients with blast phase, hematopoietic reconstitution, disease markers, donor chimerism, and treatment of relapse.
Conclusions
The review outlines new transplant platforms which are now available for patients with myelofibrosis, together with persisting problems, among which, older age combined with marrow fibrosis and an inflammatory disease. Relapse also requires aggressive monitoring of drivers mutations, and early cellular therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Divison of Leukemia, Department of Hematology and Hemopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
- Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy.
ORCID-Profile: Haris Ali
Zitieren
APA
Ali, H., & Bacigalupo, A. (2024). 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. American Journal of Hematology. https://doi.org/10.1002/ajh.27274
Vancouver
Ali H, Bacigalupo A. 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. American Journal of Hematology. 2024. doi:10.1002/ajh.27274
BibTeX
@article{Ali2024,
author = {Ali, Haris and Bacigalupo, Andrea},
title = {2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27274}
}
EUVIMED